Journal article
Anti-VEGF therapy and the retina: an update
- Abstract:
- Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of retinal vasogenic conditions. These drugs are now commonly employed for the treatment of a plethora of ocular pathologies including choroidal neovascularisation, diabetic macular oedema, and retinal vein occlusion to name a few. In this paper, we will explore the current use of anti-VEGF in a variety of retinal diseases and the impact that these medications have had on visual outcome for patients.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.3MB, Terms of use)
-
- Publisher copy:
- 10.1155/2015/627674
Authors
- Publisher:
- Hindawi Publishing
- Journal:
- Journal of Ophthalmology More from this journal
- Volume:
- 2015
- Pages:
- 1-13
- Publication date:
- 2015-01-01
- DOI:
- EISSN:
-
2090-0058
- ISSN:
-
2090-004X
- Pubs id:
-
pubs:571371
- UUID:
-
uuid:c353e482-a475-4468-8688-4fc932ea5ed8
- Local pid:
-
pubs:571371
- Source identifiers:
-
571371
- Deposit date:
-
2015-10-26
- ARK identifier:
Terms of use
- Copyright holder:
- Tah et al
- Copyright date:
- 2015
- Notes:
- Copyright © 2015 Vikas Tah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record